Immuron (IMRN) Stock Price, News & Analysis

Company Overview

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

Key Stats

• Today's Range: $0.82 to $0.83
• 50-Day Range: $0.70 to $0.96
• 52-Week Range: $0.68 to $2.39
• Volume: 929 shs
• Average Volume: 37,153 shs
• Market Capitalization: $6.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Immuron Stock Analysis - MarketRank™

Immuron scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Immuron has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Immuron has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Immuron has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.15% of the float of Immuron has been sold short.

Short Interest Ratio / Days to Cover

Immuron has a short interest ratio ("days to cover") of 0.57, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Immuron has recently increased by 109.69%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immuron does not currently pay a dividend.

Dividend Growth

Immuron does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Immuron has a news sentiment score of 1.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Immuron this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Immuron insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.01% of the stock of Immuron is held by insiders.

Percentage Held by Institutions

0.12% of the stock of Immuron is held by institutions.

IMRN Stock Analysis - Frequently Asked Questions

How have IMRN shares performed this year?

Immuron's stock was trading at $0.7680 at the beginning of 2026. Since then, IMRN shares have increased by 7.6% and is now trading at $0.8260.

How were Immuron's earnings last quarter?

Immuron (NASDAQ:IMRN) announced its earnings results on Wednesday, February, 25th. The company reported ($0.10) earnings per share for the quarter. The company earned $1.40 million during the quarter.

When did Immuron IPO?

Immuron (IMRN) raised $6 million in an initial public offering on Friday, June 9th 2017. The company issued 600,000 shares at $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) served as the underwriters for the IPO and WallachBeth Capital was co-manager.

How do I buy shares of Immuron?

Shares of IMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Immuron own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immuron investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), AbbVie (ABBV), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP) and Dynavax Technologies (DVAX).

Company Calendar

• Last Earnings: 2/25/2026
• Today: 5/08/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: NASDAQ:IMRN
• CIK: 1660046
• Web: www.immuron.com.au
• Phone: (138) 892-4854
• Fax: 6103 98227735
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.04
• Quick Ratio: 6.83

Sales & Book Value

• Annual Sales: $4.72 million
• Price / Sales: 1.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.78 per share
• Price / Book: 1.06

Miscellaneous

• Outstanding Shares: 8,170,000
• Free Float: 7,594,000
• Market Cap: $6.75 million
• Optionable: Not Optionable
• Beta: 0.87